Summary

A novel biomarker, mid-regional pro-adrenomedullin (MR-proADM), has been shown to predict mortality among patients with heart failure better than the established biomarkers for prognosis that currently are available. MR-proADM was compared with brain natriuretic peptide (BNP) and NT-proBNP (a biologic fragment associated with BNP) in the BACH trial [NCT00537628], which is the largest biomarker study to be done in the setting of suspected heart failure.